Trials / Completed
CompletedNCT02397603
Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine Induced Paravertebral Block in Patients Undergonig Thoracotomy
Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Paravertebral Block in Patients Undergoing Thoracotomy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Cairo University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effect of adding dexmedetomidine as an adjuvant to bupivacaine in patients undergoing thoracotomy when administered peri-neurally in thoracic paravertebral space.
Detailed description
Thoracotomy is associated with severe postoperative pain that could be reduced with an aggressive analgesic therapy in the early postoperative period. The use of thoracic paravertebral block is an effective analgesic approach for post-thoracotomy pain. Several local anesthetic adjuvants have been reported to extend the duration of paravertebral block. Alpha-2 agonists including dexmedetomidine appear to be the most effective in this context. The study will include an intervention group which will receive a combination of 20 ml bupivacaine 0.5% and dexmedetomidine 0.5 ml (50 microgram). The control group will receive 20 ml bupivacaine 0.5% plus 0.5 ml normal saline perineurally. Thoracic paravertebral catheter will be inserted preoperatively. Visual analogue pain score will be assessed at different intervals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dexmedetomidine bupivacaine | perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block |
| DRUG | Bupivacaine saline | perineural bupivacaine saline mixture in the thoracic paravertebral catheter |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-11-01
- Completion
- 2015-12-01
- First posted
- 2015-03-25
- Last updated
- 2016-02-02
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT02397603. Inclusion in this directory is not an endorsement.